Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

Comment

Paul D P Pharoah et al. J Natl Cancer Inst. 2012.

. 2012 Aug 22;104(16):1263-4; author reply 1266-8.

doi: 10.1093/jnci/djs312. Epub 2012 Jul 31.

No abstract available

Comment on

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists. Rae JM, et al. J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6. J Natl Cancer Inst. 2012. PMID: 22395643 Free PMC article.
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group. Regan MM, et al. J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6. J Natl Cancer Inst. 2012. PMID: 22395644 Free PMC article. Clinical Trial.
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
Kelly CM, Pritchard KI. Kelly CM, et al. J Natl Cancer Inst. 2012 Mar 21;104(6):427-8. doi: 10.1093/jnci/djs139. Epub 2012 Mar 6. J Natl Cancer Inst. 2012. PMID: 22395645 No abstract available.